Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.

Low-dose morphine better than weak opioids for moderate cancer pain

17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

The study subjects were randomized to receive either low-dose morphine (n=118) or a weak-opioid agent (n=122). A 20 percent pain intensity reduction was seen in 88.2 percent of the subjects in the morphine group and 57.7 percent in the weak-opioid group (P=0.001).

The morphine group also had a higher percentage of responders by week 1 of treatment. In addition, the same treatment group had significantly higher clinically meaningful (more than 30 percent) and highly meaningful (more than 50 percent) pain reduction.

Inadequate analgesia in the weak-opioid group resulted to frequent change in the assigned treatment.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.